CN114450306B - 抗egfr/抗4-1bb双特异性抗体及其用途 - Google Patents

抗egfr/抗4-1bb双特异性抗体及其用途 Download PDF

Info

Publication number
CN114450306B
CN114450306B CN202080053851.6A CN202080053851A CN114450306B CN 114450306 B CN114450306 B CN 114450306B CN 202080053851 A CN202080053851 A CN 202080053851A CN 114450306 B CN114450306 B CN 114450306B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
egfr
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080053851.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114450306A (zh
Inventor
龙睿朎
郑义静
郑惠真
朴庚秀
孙源晙
李良顺
金衍周
成恩实
金荣光
朴泳炖
朴敏智
严在铉
崔孝朱
宋武泳
李娜来
朴永奉
李垠政
李珢贞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liu Hanyangxing
Original Assignee
Liu Hanyangxing
ABL Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liu Hanyangxing, ABL Bio Inc filed Critical Liu Hanyangxing
Priority to CN202410360186.5A priority Critical patent/CN118221825A/zh
Publication of CN114450306A publication Critical patent/CN114450306A/zh
Application granted granted Critical
Publication of CN114450306B publication Critical patent/CN114450306B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080053851.6A 2019-07-26 2020-07-27 抗egfr/抗4-1bb双特异性抗体及其用途 Active CN114450306B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410360186.5A CN118221825A (zh) 2019-07-26 2020-07-27 抗egfr/抗4-1bb双特异性抗体、用途、制备方法及编码多核苷酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878977P 2019-07-26 2019-07-26
US62/878,977 2019-07-26
PCT/KR2020/009870 WO2021020845A1 (en) 2019-07-26 2020-07-27 Anti-egfr/anti-4-1bb bispecific antibody and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410360186.5A Division CN118221825A (zh) 2019-07-26 2020-07-27 抗egfr/抗4-1bb双特异性抗体、用途、制备方法及编码多核苷酸

Publications (2)

Publication Number Publication Date
CN114450306A CN114450306A (zh) 2022-05-06
CN114450306B true CN114450306B (zh) 2024-04-05

Family

ID=74189704

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080053851.6A Active CN114450306B (zh) 2019-07-26 2020-07-27 抗egfr/抗4-1bb双特异性抗体及其用途
CN202410360186.5A Pending CN118221825A (zh) 2019-07-26 2020-07-27 抗egfr/抗4-1bb双特异性抗体、用途、制备方法及编码多核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410360186.5A Pending CN118221825A (zh) 2019-07-26 2020-07-27 抗egfr/抗4-1bb双特异性抗体、用途、制备方法及编码多核苷酸

Country Status (11)

Country Link
US (2) US12168690B2 (enExample)
EP (1) EP4004053A4 (enExample)
JP (2) JP7738545B2 (enExample)
KR (1) KR20220038767A (enExample)
CN (2) CN114450306B (enExample)
AU (1) AU2020320349A1 (enExample)
BR (1) BR112022001329A2 (enExample)
CA (1) CA3147420A1 (enExample)
MX (1) MX2022001027A (enExample)
WO (1) WO2021020845A1 (enExample)
ZA (1) ZA202200905B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008870A2 (pt) 2019-08-12 2021-11-30 Abl Bio Inc Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
CN118369340A (zh) * 2021-11-25 2024-07-19 盛禾(中国)生物制药有限公司 一种双特异性抗原结合蛋白
JP2025512915A (ja) * 2022-04-07 2025-04-22 ユハン コーポレーション Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物
EP4644417A4 (en) * 2022-12-30 2026-02-11 Abclon Inc AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE
KR20240164748A (ko) * 2023-05-12 2024-11-20 앱클론(주) 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체
KR102927129B1 (ko) 2025-03-18 2026-02-11 이트너스 주식회사 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928893A (en) * 1995-04-08 1999-07-27 Lg Chemical Ltd. Monoclonal antibody specific for human 4-1BB and cell line producing same
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
WO2020102233A1 (en) * 2018-11-13 2020-05-22 Jn Biosciences Llc Bispecific antibodies for activation of immune cells
WO2020107715A1 (en) * 2018-11-30 2020-06-04 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
CN113166265A (zh) * 2019-08-12 2021-07-23 天境生物科技(上海)有限公司 抗紧密连接蛋白18.2和抗4-1bb双特异性抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
PL1871805T3 (pl) 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
EP3539981A1 (en) * 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
SG11201601542SA (en) * 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
EP3356401B1 (en) * 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
JP2019513373A (ja) 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
EP3445788B1 (en) * 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
KR102702926B1 (ko) 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
EP3655439A1 (en) * 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
JP7702961B6 (ja) * 2020-02-28 2025-07-17 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928893A (en) * 1995-04-08 1999-07-27 Lg Chemical Ltd. Monoclonal antibody specific for human 4-1BB and cell line producing same
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
WO2020102233A1 (en) * 2018-11-13 2020-05-22 Jn Biosciences Llc Bispecific antibodies for activation of immune cells
WO2020107715A1 (en) * 2018-11-30 2020-06-04 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
CN113166250A (zh) * 2018-11-30 2021-07-23 Abl生物公司 抗4-1bb抗体及其用途
CN113166265A (zh) * 2019-08-12 2021-07-23 天境生物科技(上海)有限公司 抗紧密连接蛋白18.2和抗4-1bb双特异性抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity;Ryutaro Asano等;Oncotarget.;13884-13893 *
肿瘤免疫治疗――遇上最好的时代;孙建;;药学进展(12);921-935 *

Also Published As

Publication number Publication date
JP7738545B2 (ja) 2025-09-12
US12168690B2 (en) 2024-12-17
US20210024638A1 (en) 2021-01-28
EP4004053A1 (en) 2022-06-01
CN118221825A (zh) 2024-06-21
CA3147420A1 (en) 2021-02-04
WO2021020845A1 (en) 2021-02-04
AU2020320349A1 (en) 2022-02-17
JP2022542670A (ja) 2022-10-06
JP2026004296A (ja) 2026-01-14
BR112022001329A2 (pt) 2022-03-22
ZA202200905B (en) 2023-11-29
CN114450306A (zh) 2022-05-06
KR20220038767A (ko) 2022-03-29
EP4004053A4 (en) 2023-10-18
US20250066487A1 (en) 2025-02-27
MX2022001027A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
CN114450306B (zh) 抗egfr/抗4-1bb双特异性抗体及其用途
CN113166250B (zh) 抗4-1bb抗体及其用途
CN114206941B (zh) 抗her2/抗4-1bb双特异性抗体及其用途
WO2020063660A1 (zh) 抗ox40抗体、其抗原结合片段及其医药用途
TW202208438A (zh) 抗ｌｉｌｒｂ１抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
CN115521377B (zh) 人表皮生长因子受体结合分子及其应用
RU2831836C2 (ru) Биспецифическое антитело анти-egfr/анти-4-1вв и его применение
RU2831838C2 (ru) Биспецифическое антитело анти-HER2/анти-4-1BB и его применение
HK40072153A (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
HK40072153B (zh) 抗egfr/抗4-1bb双特异性抗体及其用途
HK40071708A (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
CN116333117B (zh) 抗表皮生长因子受体抗体及其制备方法和用途
HK40071708B (zh) 抗her2/抗4-1bb双特异性抗体及其用途
CN118974095A (zh) 用于治疗或预防her2低表达水平的癌症的药物组合物
JP7080896B2 (ja) 抗ｄｒ５抗体およびその用途
WO2025015713A1 (zh) 抗trem2人源化抗体、其抗原结合片段及其应用
HK40113710A (zh) 用於治疗或预防her2低表达水平的癌症的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072153

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20250516

Address after: Seoul special city

Patentee after: Liu Hanyangxing

Country or region after: Republic of Korea

Address before: Gyeonggi Do, South Korea

Patentee before: ABL BIO Inc.

Country or region before: Republic of Korea

Patentee before: Liu Hanyangxing

TR01 Transfer of patent right